摘要
目的:观察术附汤联合曲美他嗪治疗经皮冠状动脉介入术(PCI)后心力衰竭患者的效果。方法:选取2020年6月至2022年12月该院收治的62例PCI术后心力衰竭患者进行前瞻性研究,按照随机数字表法将其分为对照组和观察组各31例。两组均予以抗心力衰竭基础治疗,在此基础上,对照组采用曲美他嗪治疗,观察组在对照组基础上联合术附汤治疗,两组均连续治疗3个月。比较两组临床疗效,治疗前后中医证候积分、心功能指标[左心室收缩末期内径(LVESD)、左心室射血分数(LVEF)、左心室短轴缩短率(LVFS)]水平、血清学指标[N末端脑钠肽前体(NT-proBNP)、可溶性致癌抑制因子2(sST2)、生长分化因子-15(GDF-15)]水平,以及不良反应发生率。结果:观察组治疗总有效率为93.55%(29/31),高于对照组的74.19%(23/31),差异有统计学意义(P<0.05);治疗后,观察组心悸气喘、面肢浮肿、烦躁出汗、口唇青紫等中医证候积分均低于对照组,差异有统计学意义(P<0.05);治疗后,观察组LVESD水平低于对照组,LVFS、LVEF水平均高于对照组,差异有统计学意义(P<0.05);治疗后,观察组NT-proBNP、sST2、GDF-15水平均低于对照组,差异有统计学意义(P<0.05);治疗期间,两组均未见明显不良反应。结论:术附汤联合曲美他嗪治疗PCI术后心力衰竭患者可提高治疗总有效率,降低中医证候积分和血清学指标水平,改善心功能指标水平,效果优于单用曲美他嗪治疗。
Objective:To observe effects of Zhufu decoction combined with Trimetazidine in treatment of patients with heart failure after percutaneous coronary intervention(PCI).Methods:A prospective study was conducted on 62 patients with heart failure after PCI admitted to the hospital from June 2020 to December 2022.According to the random number table method,they were divided into control group and observation group,31 cases in each group.Both groups were given anti-heart failure basic treatment.On this basis,the control group was treated with Trimetazidine,while the observation group was treated with Zhufu decoction on the basis of that of the control group.Both groups were treated continuously for 3 months.The clinical efficacy,the Traditional Chinese Medicine(TCM) syndrome score,the cardiac function indexes [left ventricular end-systolic diameter(LVESD),left ventricular ejection fraction(LVEF),left ventricular fractional shortening(LVFS)] levels,the serological indexes [N-terminal pro-brain natriuretic peptide(NT-proBNP),soluble suppression of tumorigenicity 2(sST2),growth differentiation factor-15(GDF-15)] levels before and after the treatment,and the incidence of adverse reactions were compared between the two groups.Results:The total effective rate of the observation group was 93.55%(29/31),which was higher than 74.19%(23/31) of the control group,and the difference was statistically significant(P<0.05).After the treatment,the scores of TCM syndromes such as palpitation and asthma,facial edema,irritability and sweating,and purple lips in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).After the treatment,the level of LVESD in the observation group was lower than that in the control group,the levels of LVFS and LVEF were higher than those in the control group,and the differences were statistically significant(P<0.05).After the treatment,the levels of NT-proBNP,sST2 and GDF-15 in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).During the treatment,there were no obvious adverse reactions in the two groups.Conclusions:Zhufu decoction combined with Trimetazidine in the treatment of the patients with heart failure after PCI can improve the total effective rate of treatment,reduce the TCM syndrome scores and serological index levels,and improve the levels of cardiac function indexes.Moreover,it is superior to single Trimetazidine treatment.
作者
班高亚
王卫国
BAN Gaoya;WANG Weiguo(Department of Cardiology of Kaifeng Hospital of Traditional Chinese Medicine,Kaifeng 475000 Henan,China)
出处
《中国民康医学》
2024年第6期95-98,共4页
Medical Journal of Chinese People’s Health
关键词
术附汤
曲美他嗪
经皮冠状动脉介入术
心力衰竭
中医证候积分
心功能
Zhufu decoction
Trimetazidine
Percutaneous coronary intervention
Heart failure
TCM syndrome score
Cardiac function
